PowerShares Dynamic Large Cap Growth ETF

Canadian Pacific Railway (CP) reported 1.5% YoY (year-over-year) total traffic volume growth in Week 49.

SWK’s short interest increased dramatically after its first-quarter earnings.

The latest short interest data as of December 30, 2017, show that Praxair’s (PX) short interest has increased since its 3Q17 earnings were announced on October 26, 2017.

Of the 31 analysts rating Priceline’s stock after the company’s 3Q17 earnings report, 19.4% (six analysts) have issued a “strong buy” rating and 58.1% (18 analysts) have issued a “buy” rating.

For the third quarter of 2017, Priceline’s (PCLN) revenue rose 20.2% YoY or year-over-year to $4.4 billion, driven by strong gross bookings growth of 19% YoY.

On October 19, Priceline (PCLN) announced its $450.0 million investment in China-based Meituan–Dianping.

For 3Q17, Priceline’s management expects its gross profit to increase 15.5%–20.5%.

Marriott is now trading at a forward EV-to-EBITDA multiple of 15.5x, compared with its average historical valuation of 13.9x since January 2008.

Marriott (MAR) has entered into a joint venture agreement with China’s Alibaba Group (BABA) with an aim to provide a seamless travel experience in China.

Total debt on Marriott’s balance sheet increased from $3.8 billion at the end of 2014 to $4.1 billion at the end of 2015 and $8.2 billion at the end of 4Q16.

Priceline has been funding some of its acquisitions through debt. Total debt on its balance sheet has risen from $3.9 billion at the end of 2014 to 6.2 billion at the end of 2015.

Alimta sales fell ~12.0% to $532.9 million in 2Q17 compared to $607.1 million in 2Q16.

Bristol-Myers Squibb (BMY) reported 12% growth in its top line to ~$4.93 billion during 1Q17 due to 13% operational growth in its revenues

Humalog reported growth of 17% to $708.4 million during 1Q17, compared to $606.3 million for 1Q16.

In 1Q17, Eli Lilly and Boehringer Ingelheim launched Synjardy XR tablets in the US for patients with type 2 diabetes.

Eli Lilly’s (LLY) Human Pharmaceuticals segment also consists of the oncology franchise. Key drugs in this franchise include Alimta, Erbitux, Cyramza, and Portrazza.

Bristol-Myers Squibb’s (BMY) latest drug, Opdivo, was the seventh drug to be approved by the FDA for the treatment of melanoma.

Erbitux’s sales fell 13% to $153.7 million in 4Q16, compared to ~$176.2 million in 4Q15.

With the strong performance of Opdivo, Bristol-Myers Squibb’s (BMY) oncology segment emerged as its largest revenue contributor in 4Q16.

The oncology franchise contributes around 18% of Lily’s total revenues.

Bristol-Myers Squibb’s (BMY) latest drug Opdivo was the seventh drug to be approved by the US FDA for the treatment of melanoma.

Due to the strong performance of Opdivo, the oncology segment has emerged as the largest revenue contributor for Bristol-Myers Squibb (BMY) in 3Q16.

Eli Lilly’s (LLY) Human Pharmaceuticals segment also contains its oncology franchise. Key drugs in this franchise include Alimta, Erbitux, and Cyramza.

Oncology franchise Eli Lilly and Co.’s (LLY) human pharmaceuticals segment also consists of the oncology franchise. The oncology franchise contributes around 18% of total revenues for Lilly. Key drugs in this segment include Alimta, Erbitux, and Cyramza. A new drug, Portrazza, launched in US markets in December 2015. Erbitux Erbitux is a drug used in […]

Bristol-Myers Squibb’s (BMY) latest drug, Opdivo ,was the seventh drug to be approved by the FDA for the treatment of melanoma. Opdivo reported revenues of $840 million in 2Q16, as compared to $122 million in 2Q15.

Another franchise from Eli Lilly’s Human Pharmaceuticals segment is the neuroscience franchise—its drugs include Zyprexa, Cymbalta, and Strattera.

Dollar General’s stock price has risen by 23.6% on a YTD basis to $89.49 as of August 16, 2016.

Major off-price retailers have strong margins supported by lean operating models, efficient inventory management, and strong vendor relationships.

Clorox’s (CLX) fiscal year-to-date cash flow generation came in at $0.3 billion, compared to $0.4 billion in the same period in 2015.

Intuitive Surgical (ISRG) has established geographical growth as one its major growth drivers after procedure growth.

Estée Lauder’s makeup segment’s net revenue rose 7.3% in reported terms and 11% in constant currency terms to $1.2 billion in fiscal 3Q16.

Dr Pepper Snapple’s stock price appreciated by ~3% to $90.38 on April 27, in reaction to the company’s strong 1Q16 results and revised outlook.

Opdivo is an oncology drug from Bristol-Myers Squibb that is already approved by the FDA and EMA for the treatment of patients with melanoma. On March 30, EMA validated the type-II variation application for extending the current indications for Opdivo.

While department stores like Macy’s struggled to report decent numbers in 2015, off-price retailers have continued to display their strength.

B&G Foods (BGS) reported that operating margin for fiscal 4Q15 rose to 14.2% compared to 12.7% in 4Q14. Operating margin for fiscal 2015 was 17.8% compared to 13.6% in 2014.

The US business of TJX Companies consists of 1,156 T.J. Maxx stores, 1,007 Marshalls stores, 526 HomeGoods stores, and eight Sierra Trading Post stores.

Hormel Foods Corporation (HRL) has a market cap of $22.7 billion. HRL fell by 3.6% to close at $42.89 per share as of February 18, 2016.

Carnival identified China as its biggest potential area of expansion. It announced that Carnival Cruise Line will enter the Chinese market in 2017.

Carnival Corporation (CCL) saw a marginal fall in its top line numbers. The revenues for 4Q15 fell by about 2.5% year-over-year to reach $3.71 billion.

The price performance of T-Mobile has been significant in the past 52 weeks as of December 10. During the period, T-Mobile’s price rose by a significant 43.6%.

Disney’s (DIS) Media Networks segment was the biggest contributor to its revenue, at 44% or $52.5 billion, in fiscal 2015.

While the power sector differs country by country, the operational structure of the sector across the world is pretty much the same.